SRI-37330
SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research[1].
Product Specifications
CAS Number
[2322245-42-9]
UNSPSC
12352005
Target
Arrestin
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/sri-37330.html
Concentration
10mM
Purity
99.16
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CS(=O)(NCC1CN(C2=C3C=C(C(F)(F)F)C=CC3=NC=N2)CCC1)=O
Molecular Formula
C16H19F3N4O2S
Molecular Weight
388.41
References & Citations
[1]Thielen LA, et al. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 Sep 1;32 (3) :353-365.e8.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
032178-ML650 100 µL
ATG16L, CT (ATG16L1, APG16L, Autophagy-related protein 16-1, APG16-like 1) (MaxLight 650) discontinued
Ask
View Details